CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CELZ
We are a commercial stage biotechnology company dedicated to the advancement regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Our platforms, therapies and products include the following:
Our subsidiary, Creative Medical Technologies, Inc. ("CMT"), was originally created to monetize U.S. Patent No. 8,372,797 and related intellectual property related to the treatment of erectile dysfunction ("ED"), which it acquired in February 2016. Subsequently, we have expanded our development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing "re-programmed" stem cells, and the treatment of neurologic disorders, lower back pain, Type-1 diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc., nor AlloCelz LLC have commenced commercial activities.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.0K | $11.0K | $9.0K | $88.6K | $87.8K | $164.5K | $165.5K | $124.4K | $4.8K | $0 |
| Cost of revenue | $2.2K | $4.4K | $3.6K | $28.5K | $47.9K | $50.6K | $45.5K | $70.4K | $8.0K | $0 |
| Gross profit | $3.8K | $6.6K | $5.4K | $60.1K | $39.8K | $113.9K | $120.0K | $54.0K | -$3.2K | $0 |
| R&D | $2.3M | $2.4M | $2.0M | $6.3M | $109.2K | $0 | $0 | $96.6K | $260.1K | $85.3K |
| SG&A | $3.8M | $3.2M | $3.6M | $3.9M | $3.0M | $1.2M | $1.2M | $1.1M | $898.5K | $665.0K |
| Total operating expenses | $6.1M | $5.8M | $5.6M | $10.3M | $3.2M | $1.2M | $1.3M | $1.2M | $1.2M | $759.7K |
| Operating income | -$6.1M | -$5.7M | -$5.6M | -$10.2M | -$3.1M | -$1.1M | -$1.1M | -$1.1M | -$1.2M | -$759.7K |
| Interest expense | — | — | — | $0 | $4.3M | $1.2M | $1.9M | $1.4M | $377.6K | $6.4K |
| Pre-tax income | -$6.0M | -$5.5M | -$5.3M | -$10.1M | $19.2M | -$36.3M | -$8.5M | -$13.7M | -$2.7M | -$766.1K |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$6.0M | -$5.5M | -$5.3M | -$10.1M | $19.2M | -$36.3M | -$8.5M | -$13.7M | -$2.7M | -$766.1K |
| EPS, basic | — | — | — | -0.93 | 7.37 | -62.69 | — | — | — | — |
| EPS, diluted | -2.52 | -3.71 | -3.76 | -0.93 | 5.61 | -62.69 | -0.82 | -3.50 | -0.03 | -0.01 |
| Shares, diluted (wtd. avg.) | 2.4M | 1.5M | 1.4M | 10.9M | 3.2M | 579,461 | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.2M | $5.9M | $3.5M | $8.3M | $10.7M | $98.0K | $88.6K | $304.1K | $13.7K | $221.9K |
| Receivables | — | — | — | $0 | $2.5K | $0 | $5.6K | $9.6K | $4.8K | $0 |
| Inventory | $0 | $2.2K | $6.6K | $10.2K | $10.9K | $0 | — | — | — | — |
| Total current assets | $7.4M | $6.1M | $10.3M | $18.7M | $10.7M | $98.0K | $94.2K | $313.7K | $18.5K | $221.9K |
| Other intangibles | $407.2K | $530.6K | $441.0K | $435.6K | $527.7K | $619.8K | $436.6K | $163.5K | $184.6K | $100.6K |
| Total assets | $7.8M | $6.7M | $10.7M | $19.2M | $11.3M | $717.8K | $530.8K | $477.2K | $203.1K | $322.5K |
| Accounts payable | $270.7K | $273.5K | $317.3K | $3.3M | $761.9K | $350.9K | $320.8K | $331.8K | $237.6K | $66.4K |
| Total current liabilities | $284.9K | $327.6K | $371.4K | $3.3M | $1.1M | $40.5M | $8.6M | $4.5M | $2.4M | $453.9K |
| Long-term debt | — | — | — | — | — | — | — | — | $493.2K | — |
| Total liabilities | $284.9K | $327.6K | $371.4K | $3.3M | $1.1M | $40.5M | $8.6M | $4.5M | $2.4M | $480.3K |
| Retained earnings | -$70.6M | -$64.6M | -$59.1M | -$53.8M | -$43.7M | -$61.9M | -$25.6M | -$17.1M | -$3.4M | -$766.6K |
| Total equity | $7.5M | $6.3M | $10.3M | $15.9M | $10.2M | -$39.8M | -$8.1M | -$4.0M | -$2.2M | -$157.8K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.9M | -$5.3M | -$8.0M | -$7.8M | -$2.2M | -$434.6K | -$1.2M | -$1.1M | -$889.6K | -$445.2K |
| Stock-based compensation | $3.5K | $36.6K | $36.6K | $68.7K | $595.4K | $170.3K | $0 | $1.9K | $144.2K | $2.6K |
| Investing cash flow | -$50.5K | $6.3M | $3.4M | -$10.1M | $0 | -$250.0K | $0 | — | $0 | -$10.0K |
| Financing cash flow | $7.2M | $1.5M | -$271.0K | $15.5M | $12.8M | $693.9K | $997.7K | $1.3M | $681.5K | $677.0K |
| Buybacks | $10.0K | $175.0K | $271.0K | $0 | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001477932-26-002534.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $4.8K | $124.4K | $165.5K | $164.5K | $87.8K | $88.6K | $9.0K | $11.0K | $6.0K |
| Gross profit | $0 | -$3.2K | $54.0K | $120.0K | $113.9K | $39.8K | $60.1K | $5.4K | $6.6K | $3.8K |
| Net income | -$766.1K | -$2.7M | -$13.7M | -$8.5M | -$36.3M | $19.2M | -$10.1M | -$5.3M | -$5.5M | -$6.0M |
Recent filings and events
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Shareholder vote Item 5.07
- Shareholder vote Item 5.07
- Officer or director change Item 5.02
- Material agreement signed Item 1.01
- Unregistered share sale Item 3.02
- Shareholder vote Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |